Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Apr;80(1-2):286–294. doi: 10.1038/sj.bjc.6690353

Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer

J H de Witte 1, C G J Sweep 1, J G M Klijn 2, N Grebenschikov 1, H A Peters 2, M P Look 2, ThH van Tienoven 1, J J T M Heuvel 1, J Bolt-De Vries 2, ThJ Benraad 1, J A Foekens 2
PMCID: PMC2362996  PMID: 10390010

Abstract

The prognostic value of tissue-type plasminogen activator (tPA) measured in samples derived from 865 patients with primary breast cancer using a recently developed enzyme-linked immunosorbent assay (ELISA) was evaluated. Since the assay could easily be adapted to the assessment of the complex of tPA with its type-1 inhibitor (PAI-1), it was investigated whether the tPA:PAI-1 complex also provides prognostic information. To this end, cytosolic extracts and corresponding detergent extracts of 100 000 g pellets obtained after ultracentrifugation when preparing the cytosolic fractions for routine steroid hormone receptor determination were assayed. Statistically significant correlations were found between the cytosolic levels and those determined in the pellet extracts (Spearman correlation coefficient rs = 0.75, P < 0.001 for tPA and r = 0.50, P < 0.001 for tPA:PAI-1 complex). In both Cox univariate and multivariate analysis elevated levels of (total) tPA determined in the pellet extracts, but not in cytosols, were associated with prolonged relapse-free (RFS) and overall survival (OS). In contrast, high levels of the tPA:PAI-1 complex measured in cytosols, but not in the pellet extracts, were associated with a poor RFS and OS. The prognostic information provided by the cytosolic tPA:PAI-1 complex was comparable to that provided by cytosolic (total) PAI-1. Furthermore, the estimated levels of free, uncomplexed tPA and PAI-1, in cytosols and in pellet extracts, were related to patient prognosis in a similar way as the (total) levels of tPA and PAI-1 respectively. Determination of specific forms of components of the plasminogen activation system, i.e. tPA:PAI-1 complex and free, uncomplexed tPA and/or PAI-1, may be considered a useful adjunct to the analyses of the separate components (tPA and/or PAI-1) and provide valuable additional prognostic information with respect to survival of breast cancer patients. © 1999 Cancer Research Campaign

Keywords: tissue-type plasminogen activator, tPA:PAI-1 complex, ELISA, cytosol, breast cancer, prognostic impact

Full Text

The Full Text of this article is available as a PDF (125.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benraad T. J., Geurts-Moespot J., Grøndahl-Hansen J., Schmitt M., Heuvel J. J., de Witte J. H., Foekens J. A., Leake R. E., Brünner N., Sweep C. G. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. Eur J Cancer. 1996 Jul;32A(8):1371–1381. doi: 10.1016/0959-8049(96)00118-9. [DOI] [PubMed] [Google Scholar]
  2. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  3. Butler W. B., Kirkland W. L., Gargala T. L., Goran N., Kelsey W. H., Berlinski P. J. Steroid stimulation of plasminogen activator production in a human breast cancer cell line (MCF-7). Cancer Res. 1983 Apr;43(4):1637–1641. [PubMed] [Google Scholar]
  4. Conese M., Blasi F. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation. Biol Chem Hoppe Seyler. 1995 Mar;376(3):143–155. [PubMed] [Google Scholar]
  5. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  6. Dudani A. K., Ganz P. R. Endothelial cell surface actin serves as a binding site for plasminogen, tissue plasminogen activator and lipoprotein(a). Br J Haematol. 1996 Oct;95(1):168–178. doi: 10.1046/j.1365-2141.1996.7482367.x. [DOI] [PubMed] [Google Scholar]
  7. Duffy M. J., O'Grady P., Devaney D., O'Siorain L., Fennelly J. J., Lijnen H. R. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res. 1988 Mar 1;48(5):1348–1349. [PubMed] [Google Scholar]
  8. Duffy M. J., O'Grady P., Simon J., Rose M., Lijnen H. R. Tissue-type plasminogen activator in breast cancer: relationship with estradiol and progesterone receptors. J Natl Cancer Inst. 1986 Sep;77(3):621–623. doi: 10.1093/jnci/77.3.621. [DOI] [PubMed] [Google Scholar]
  9. Duffy M. J. Proteases as prognostic markers in cancer. Clin Cancer Res. 1996 Apr;2(4):613–618. [PubMed] [Google Scholar]
  10. Duggan C., Kennedy S., Kramer M. D., Barnes C., Elvin P., McDermott E., O'Higgins N., Duffy M. J. Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer. 1997;76(5):622–627. doi: 10.1038/bjc.1997.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Egelund R., Schousboe S. L., Sottrup-Jensen L., Rodenburg K. W., Andreasen P. A. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. Eur J Biochem. 1997 Sep 15;248(3):775–785. doi: 10.1111/j.1432-1033.1997.t01-1-00775.x. [DOI] [PubMed] [Google Scholar]
  12. Foekens J. A., Portengen H., van Putten W. L., Peters H. A., Krijnen H. L., Alexieva-Figusch J., Klijn J. G. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res. 1989 Nov 1;49(21):5823–5828. [PubMed] [Google Scholar]
  13. Grebenschikov N., Geurts-Moespot A., De Witte H., Heuvel J., Leake R., Sweep F., Benraad T. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers. 1997 Jan-Mar;12(1):6–14. doi: 10.1177/172460089701200102. [DOI] [PubMed] [Google Scholar]
  14. Grøndahl-Hansen J., Bach F., Munkholm-Larsen P. Tissue-type plasminogen activator in plasma from breast cancer patients determined by enzyme-linked immunosorbent assay. Br J Cancer. 1990 Mar;61(3):412–414. doi: 10.1038/bjc.1990.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hansson P. O., Eriksson H., Eriksson E., Jagenburg R., Lukes P., Risberg B. Can laboratory testing improve screening strategies for deep vein thrombosis at an emergency unit? J Intern Med. 1994 Feb;235(2):143–151. doi: 10.1111/j.1365-2796.1994.tb01048.x. [DOI] [PubMed] [Google Scholar]
  16. Hekman C. M., Loskutoff D. J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem. 1985 Sep 25;260(21):11581–11587. [PubMed] [Google Scholar]
  17. Jänicke F., Schmitt M., Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost. 1991 Jul;17(3):303–312. doi: 10.1055/s-2007-1002624. [DOI] [PubMed] [Google Scholar]
  18. Layer G. T., Burnand K. G., Gaffney P. J., Cederholm-Williams S. A., Mahmoud M., Houlbrook S., Pattison M. Tissue plasminogen activators in breast cancer. Thromb Res. 1987 Mar 1;45(5):601–607. doi: 10.1016/0049-3848(87)90323-9. [DOI] [PubMed] [Google Scholar]
  19. Levin E. G., Santell L., Osborn K. G. The expression of endothelial tissue plasminogen activator in vivo: a function defined by vessel size and anatomic location. J Cell Sci. 1997 Jan;110(Pt 2):139–148. doi: 10.1242/jcs.110.2.139. [DOI] [PubMed] [Google Scholar]
  20. Maser R. E., Ellis D., Erbey J. R., Orchard T. J. Do tissue plasminogen activator-plasminogen activator inhibitor-1 complexes relate to the complications of insulin-dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications. 1997 Jul-Aug;11(4):243–249. doi: 10.1016/s1056-8727(96)00040-2. [DOI] [PubMed] [Google Scholar]
  21. Mignatti P., Rifkin D. B. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 1993 Jan;73(1):161–195. doi: 10.1152/physrev.1993.73.1.161. [DOI] [PubMed] [Google Scholar]
  22. Mira-y-Lopez R., Ossowski L. Hormonal modulation of plasminogen activator: an approach to prediction of human breast tumor responsiveness. Cancer Res. 1987 Jul 1;47(13):3558–3564. [PubMed] [Google Scholar]
  23. Needham G. K., Nicholson S., Angus B., Farndon J. R., Harris A. L. Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors. Cancer Res. 1988 Nov 15;48(22):6603–6607. [PubMed] [Google Scholar]
  24. Niwano H., Takahashi H., Tatewaki W., Wada K., Seki Y., Shibata A. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states. Blood Coagul Fibrinolysis. 1992 Aug;3(4):389–393. [PubMed] [Google Scholar]
  25. Pai M. N. Changes in Personality after Cerebrospinal Fever. Br Med J. 1945 Mar 3;1(4391):289–293. doi: 10.1136/bmj.1.4391.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Rella C., Coviello M., Quaranta M., Paradiso A. Tissue-type plasminogen activator as marker of functional steroid receptors in human breast cancer. Thromb Res. 1993 Jan 15;69(2):209–220. doi: 10.1016/0049-3848(93)90046-q. [DOI] [PubMed] [Google Scholar]
  27. Rijken D. C. Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Baillieres Clin Haematol. 1995 Jun;8(2):291–312. doi: 10.1016/s0950-3536(05)80269-0. [DOI] [PubMed] [Google Scholar]
  28. Schmitt M., Harbeck N., Thomssen C., Wilhelm O., Magdolen V., Reuning U., Ulm K., Höfler H., Jänicke F., Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost. 1997 Jul;78(1):285–296. [PubMed] [Google Scholar]
  29. Schmitt M., Jänicke F., Graeff H. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul Fibrinolysis. 1990 Dec;1(6):695–702. [PubMed] [Google Scholar]
  30. Yamashita J., Ogawa M., Sakai K. Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery. 1995 Jun;117(6):601–608. doi: 10.1016/s0039-6060(95)80001-8. [DOI] [PubMed] [Google Scholar]
  31. Yamashita J., Ogawa M., Yamashita S., Nakashima Y., Saishoji T., Nomura K., Inada K., Kawano I. Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. Br J Cancer. 1993 Sep;68(3):524–529. doi: 10.1038/bjc.1993.380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. de Bruin P. A., Griffioen G., Verspaget H. W., Verheijen J. H., Dooijewaard G., van den Ingh H. F., Lamers C. B. Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res. 1988 Aug 15;48(16):4520–4524. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES